Ογ½ΆΚΣΖ΅

Skip to main content
Josef T. Prchal
( out of 73 reviews )

Josef T. Prchal, MD

Languages spoken: English, Czech

Clinical Locations

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
Salt Lake City
801-585-2626

Veterans Administration Medical Center

Myeloproliferative Disorders Clinic
Salt Lake City
801-585-2626
  • Josef Prchal, MD is a Professor in the Division of Hematology and Hematologic Malignancies, Department of Internal Medicine at the Ογ½ΆΚΣΖ΅ of Utah. He is also named Huntsman Cancer Institute Investigator, and is a member of the Cell Response and Regulation Program and the Imaging, Diagnostics, and Therapeutics Program. In addition, he holds adjunct Professor appointments in Human Genetics and in Pathology. At his clinics at Huntsman Cancer Institute's Clinic 2B and at the George E. Wahlen Veteran's Medical Center, he sees benign red cell disorders and Philadelphia chromosome-negative myeloproliferative neoplasms.

    For questions regarding Dr. Prchal's practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at www.huntsmancancer.org or (801) 587-4630.

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    Educational Commission for Foreign Medical Graduates
    Licentiate of the Medical Council of Canada
    Royal College of Physicians and Surgeons of Canada
    Royal College of Surgeons of Canada

    Patient Rating

    4.9 /5
    ( out of 73 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    July 20, 2024
    HUNTSMAN CANCER CENTER

    What a marvelous and devoted medical man! So glad we met. I look forward to seeing his capable hands at my treatment sessions.

    July 19, 2024
    HUNTSMAN CANCER CENTER

    I am fortunate to have him as my Dr. He is wonderful!

    June 30, 2024
    HUNTSMAN CANCER CENTER

    There's nobody in the world better at dealing with ET than Dr. Prchal and I appreciate him being here.

    June 29, 2024
    HUNTSMAN CANCER CENTER

    He is amazing and I am grateful to be his patient. I had a difficulty with scheduling only. It has been resolved...

    June 28, 2024
    HUNTSMAN CANCER CENTER

    Dr. Prchal was concerned about one of my symptoms. He scheduled me to return the next week.-.

    June 07, 2024
    HUNTSMAN CANCER CENTER

    A kind, knowledgeable, and interesting human being, who is interested in his patients.

    May 25, 2024
    HUNTSMAN CANCER CENTER

    A ray of sunshine, knowledge and expertise! Dr. Prchal is a "master." He shows genuine interest in his patients as individuals.

    April 16, 2024
    HUNTSMAN CANCER CENTER

    I so appreciate having someone of Dr PrchalΒΏs ability, concern and warmth available to care for me.

    April 12, 2024
    HUNTSMAN CANCER CENTER

    Dr Prchal has restored my faith in the healthcare.

  • Josef Prchal, MD is a Professor in the Division of Hematology and Hematologic Malignancies, Department of Internal Medicine at the Ογ½ΆΚΣΖ΅ of Utah. He is also named Huntsman Cancer Institute Investigator, and is a member of the Cell Response and Regulation Program and the Imaging, Diagnostics, and Therapeutics Program. In addition, he holds adjunct Professor appointments in Human Genetics and in Pathology. At his clinics at Huntsman Cancer Institute's Clinic 2B and at the George E. Wahlen Veteran's Medical Center, he sees benign red cell disorders and Philadelphia chromosome-negative myeloproliferative neoplasms.

    For questions regarding Dr. Prchal's practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at or (801) 587-4630.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Human Genetics -Adjunct
    Academic Divisions Hematology
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    Educational Commission for Foreign Medical Graduates
    Licentiate of the Medical Council of Canada
    Royal College of Physicians and Surgeons of Canada
    Royal College of Surgeons of Canada

    Education history

    Fellowship Laboratory and Clinical Hematology - Toronto General Hospital Fellow
    Pathology - Ογ½ΆΚΣΖ΅ of Toronto, Department of Medicine Resident
    Research Fellow Research - City of Hope National Medical Center Research Fellow
    Hematology/Oncology - Ογ½ΆΚΣΖ΅ of Toronto, Department of Medicine Fellow
    Residency Internal Medicine - Ογ½ΆΚΣΖ΅ of Toronto, Dept of Medicine Resident
    Rotating Internship - Ογ½ΆΚΣΖ΅ of Toronto, Dept of Medicine Intern
    Fellowship Biochemistry - Charles Ογ½ΆΚΣΖ΅ School of Medicine Postdoctoral Research Associate
    Charles Ογ½ΆΚΣΖ΅ M.D.

    Selected Publications

    Journal Article

    1. Song J, Lanikova L, Kim SJ, Papadopoulos N, Meznarich J, Constantinescu SN, Parsegov B, Prchal JF, Prchal JT (2024). Novel germline JAK2(R715T) mutation causing PV-like erythrocytosis in 3 generations. Amelioration by Ropeg-Interferon. Am J Hematol, 99(7), 1220-1229. ()
    2. Prchal JT, Lichtman MA (2023). Measurement of red cell, plasma, and blood volume: A perspective. Am J Hematol, 99(1), 9-11. ()
    3. Yoo JJ, Cohen HJ, Artz AS, Price E, Fill JA, Prchal J, Sapp S, Barnhart H, from the Partnership for Anemia Clinical and Translational Trials in the Elderly PACTTE (2024). Biomarkers of erythropoiesis response to intravenous iron in a crossover pilot study in unexplained anemia of the elderly. Hematology, 28(1), 1-8. ()
    4. Trunk AD, Patel SS, Prchal JT, Sborov DW, Zander AR, Lee CJ (2023). Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide. Leuk Res Rep, 20, 100388. ()
    5. Zhang X, Song J, Shah BN, Han J, Hassan T, Miasniakova G, Sergueeva A, Nekhai S, Machado RF, Gladwin MT, Saraf SL, Prchal JT, Gordeuk VR (2023). Gene expression changes in sickle cell reticulocytes and their clinical associations. Sci Rep, 13(1), 12864. ()
    6. Shah BN, Zhang X, Sergueeva AI, Miasnikova GY, Ganz T, Prchal JT, Gordeuk VR (2023). Increased transferrin protects from thrombosis in Chuvash erythrocytosis. Am J Hematol. ()
    7. Song J, Sundar KM, Horvathova M, Gangaraju R, Indrak K, Christensen RD, Genzor S, Lundby C, Divoky V, Ganz T, Prchal JT (2023). Increased blood reactive oxygen species and hepcidin in obstructive sleep apnea precludes expected erythrocytosis. Am J Hematol. ()
    8. Prchal JT, Semenza GL (2023). On either side of homeostasis: EPAS1 gain and loss of function mutations. Haematologica. ()
    9. Kragesteen BK, Giladi A, David E, Halevi S, Geirsdttir L, Lempke OM, Li B, Bapst AM, Xie K, Katzenelenbogen Y, Dahl SL, Sheban F, Gurevich-Shapiro A, Zada M, Phan TS, Avellino R, Wang SY, Barboy O, Shlomi-Loubaton S, Winning S, Markwerth PP, Dekalo S, Keren-Shaul H, Kedmi M, Sikora M, Fandrey J, Korneliussen TS, Prchal JT, Rosenzweig B, Yutkin V, Racimo F, Willerslev E, Gur C, Wenger RH, Amit I (2023). The transcriptional and regulatory identity of erythropoietin producing cells. Nat Med, 29(5), 1191-1200. ()
    10. Song J, Kim SJ, Gollamudi J, Thiagarajan P, Prchal JT (2022). Downregulated KLF2 in polycythemia vera and essential thrombocythemia induces prothrombotic gene expression. Blood Adv, 7(5), 712-717. ()
    11. Amaru R, Song J, Reading NS, Gordeuk VR, Prchal JT (2023). "What We Know and What We Do Not Know about Evolutionary Genetic Adaptation to High Altitude Hypoxia in Andean Aymaras". Genes (Basel), 14(3). ()
    12. Kralova B, Sochorcova L, Song J, Jahoda O, Hlusickova Kapralova K, Prchal JT, Divoky V, Horvathova M (2022). Developmental changes in iron metabolism and erythropoiesis in mice with human gain-of-function erythropoietin receptor. Am J Hematol, 97(10), 1286-1299. ()
    13. Mascarenhas J, Kosiorek HE, Prchal JT, Rambaldi A, Berenzon D, Yacoub A, Harrison CN, McMullin MF, Vannucchi AM, Ewing J, OConnell CL, Kiladjian JJ, Mead AJ, Winton EF, Leibowitz DS, De Stefano V, Arcasoy MO, Kessler CM, Catchatourian R, Rondelli D, Silver RT, Bacigalupo A, Nagler A, Kremyanskaya M, Levine MF, Arango Ossa JE, McGovern E, Sandy L, Salama ME, Najfeld V, Tripodi J, Farnoud N, Penson AV, Weinberg RS, Price L, Goldberg JD, Barbui T, Marchioli R, Tognoni G, Rampal RK, Mesa RA, Dueck AC, Hoffman R (2021). A randomized phase 3 trial of interferon-Ξ± vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood, 139(19), 2931-2941. ()
    14. Talpaz M, Prchal J, Afrin L, Arcasoy M, Hamburg S, Clark J, Kornacki D, Colucci P, Verstovsek S (2021). Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 - 100β€―Γ—β€―10(9)/L): Final Analysis of an Open-Label Phase 2 Study. Clin Lymphoma Myeloma Leuk, 22(5), 336-346. ()
    15. Bahr TM, Agarwal AM, Meznarich JA, Prince WL, Wait TWP, Prchal JT, Christensen RD (2021). Thirty-five males with severe (Class 1) G6PD deficiency (c.637G>T) in a North American family of European ancestry. Blood Cells Mol Dis, 92, 102625. ()
    16. Shrimali NM, Agarwal S, Kaur S, Bhattacharya S, Bhattacharyya S, Prchal JT, Guchhait P (2021). Ξ±-Ketoglutarate Inhibits Thrombosis and Inflammation by Prolyl Hydroxylase-2 Mediated Inactivation of Phospho-Akt. EBioMedicine, 73, 103672. ()
    17. Abou-Ismail MY, Prchal JT, Deininger MW, Parker CJ, Lim MY (2021). Anticoagulation management post-transjugular intrahepatic portosystemic shunt in portal hypertension associated with myeloproliferative neoplasms. Blood Coagul Fibrinolysis, 32(8), 578-583. ()
    18. Sirdah M, Reading NS, Vankayalapati H, Prchal JT (2021). A computational study of structural differences of binding of NADP+ and G6P substrates to G6PD Mediterraneanc.563T, G6PD A-c.202A/c.376G, G6PD Cairoc.404C and G6PD Gazac.536A mutations. Blood Cells Mol Dis, 89, 102572. ()
    19. Bhattacharya S, Shrimali NM, Mohammad G, Koul PA, Prchal JT, Guchhait P (2021). Gain-of-function Tibetan PHD2D4E;C127S variant suppresses monocyte function: A lesson in inflammatory response to inspired hypoxia. EBioMedicine, 68, 103418. ()
    20. Feusier JE, Arunachalam S, Tashi T, Baker MJ, VanSant-Webb C, Ferdig A, Welm BE, Rodriguez-Flores JL, Ours C, Jorde LB, Prchal JT, Mason CC (2021). Large-Scale Identification of Clonal Hematopoiesis and Mutations Recurrent in Blood Cancers. Blood Cancer Discov, 2(3), 226-237. ()
    21. Thiagarajan P, Parker CJ, Prchal JT (2021). How Do Red Blood Cells Die? Front Physiol, 12, 655393. ()
    22. Chan XY, Volkova E, Eoh J, Black R, Fang L, Gorashi R, Song J, Wang J, Elliott MB, Barreto-Ortiz SF, Chen J, Lin BL, Santhanam L, Cheng L, Lee FS, Prchal JT, Gerecht S (2021). HIF2A gain-of-function mutation modulates the stiffness of smooth muscle cells and compromises vascular mechanics. iScience, 24(4), 102246. ()
    23. Gordeuk VR, Shah BN, Zhang X, Thuma PE, Zulu S, Moono R, Reading NS, Song J, Zhang Y, Nouraie M, Campbell A, Minniti CP, Rana SR, Darbari DS, Kato GJ, Niu M, Castro OL, Machado R, Gladwin MT, Prchal JT (2020). The CYB5R3c .350C>G and G6PD A alleles modify severity of anemia in malaria and sickle cell disease. Am J Hematol, 95(11), 1269-1279. ()
    24. Xu G, van Bruggen R, Gualtieri CO, Moradin N, Fois A, Vallerand D, De Sa Tavares Russo M, Bassenden A, Lu W, Tam M, Lesage S, Girouard H, Avizonis DZ, Deblois G, Prchal JT, Stevenson M, Berghuis A, Muir T, Rabinowitz J, Vidal SM, Fodil N, Gros P (2019). Bisphosphoglycerate Mutase Deficiency Protects against Cerebral Malaria and Severe Malaria-Induced Anemia. Cell Rep, 32(12), 108170. ()
    25. Bahr TM, Henry E, Hulse W, Baer VL, Prchal JT, Bhutani VK, Christensen RD (2020). Early Hyperbilirubinemia in Neonates with Down Syndrome. J Pediatr, 219, 140-145. ()
    26. Gangaraju R, Song J, Kim SJ, Tashi T, Reeves BN, Sundar KM, Thiagarajan P, Prchal JT (2019). Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia. Blood Adv, 4(6), 1115-1130. ()
    27. Swierczek S, Prchal JT (2020). Clonal hematopoiesis in hematological disorders: Three different scenarios. Exp Hematol, 83, 57-65. ()
    28. Patel AB, Franzini A, Leroy E, Kim SJ, Pomicter AD, Genet L, Xiao M, Yan D, Ahmann JM, Agarwal AM, Clair P, Addada J, Lambert J, Salmon M, Gleich GJ, Cross NCP, Constantinescu SN, OHare T, Prchal JT, Deininger MW (2019). JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera. Blood, 134(26), 2388-2398. ()
    29. Babosova O, Kapralova K, Raskova Kafkova L, Korinek V, Divoky V, Prchal JT, Lanikova L (2019). Iron chelation and 2-oxoglutarate-dependent dioxygenase inhibition suppress mantle cell lymphoma's cyclin D1. J Cell Mol Med, 23(11), 7785-7795. ()
    30. Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Papaemmanuil E, Salama M, Singer-Weinberg R, Rampal R, Goldberg JD, Barbui T, Mesa R, Dueck AC, Hoffman R (2019). Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood, 134(18), 1498-1509. ()
    31. Lanikova L, Babosova O, Prchal JT (2019). Experimental Modeling of Myeloproliferative Neoplasms. Genes (Basel), 10(10). ()
    32. Bretz CA, Divoky V, Prchal J, Kunz E, Simmons AB, Wang H, Hartnett ME (2018). Erythropoietin Signaling Increases Choroidal Macrophages and Cytokine Expression, and Exacerbates Choroidal Neovascularization. Sci Rep, 8(1), 2161. ()
    33. Kovacsovics-Bankowski M, Kelley TW, Efimova O, Kim SJ, Wilson A, Swierczek S, Prchal J (2016). Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2(V617F) allelic burden. Exp Hematol Oncol, 5, 28. ()
    34. Christensen RD, Malleske DT, Lambert DK, Baer VL, Prchal JT, Denson LE, Gerday E, Weaver Lewis KA, Shepherd JG (2015). Measuring End-Tidal Carbon Monoxide of Jaundiced Neonates in the Birth Hospital to Identify Those with Hemolysis. Neonatology, 109(1), 1-5. ()
    35. Nussenzveig RH, Pham HT, Perkins SL, Prchal JT, Agarwal AM, Salama ME (2015). Increased frequency of co-existing JAK2 exon-12 or MPL exon-10 mutations in patients with low JAK2(V617F) allelic burden. Leuk Lymphoma, 57(6), 1429-35. ()
    36. Ge RL, Simonson TS, Gordeuk V, Prchal JT, McClain DA (2015). Metabolic aspects of high-altitude adaptation in Tibetans. Exp Physiol, 100(11), 1247-55. ()
    37. Simonson TS, Huff CD, Witherspoon DJ, Prchal JT, Jorde LB (2015). Adaptive genetic changes related to haemoglobin concentration in native high-altitude Tibetans. Exp Physiol, 100(11), 1263-8. ()
    38. Prchal JT (2015). Genetic selection by high altitude: Beware of experiments at ambient conditions. Proc Natl Acad Sci U S A, 112(33), 10080-1. ()
    39. Song J, Yoon D, Christensen RD, Horvathova M, Thiagarajan P, Prchal JT (2015). HIF-mediated increased ROS from reduced mitophagy and decreased catalase causes neocytolysis. J Mol Med (Berl), 93(8), 857-66. ()
    40. Pomicter AD, Eiring AM, Senina AV, Zabriskie MS, Marvin JE, Prchal JT, OHare T, Deininger MW (2015). Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm. Exp Hematol, 43(7), 537-45.e1-11. ()
    41. Christensen RD, Lambert DK, Henry E, Yaish HM, Prchal JT (2014). End-tidal carbon monoxide as an indicator of the hemolytic rate. Blood Cells Mol Dis, 54(3), 292-6. ()
    42. Price E, Artz AS, Barnhart H, Sapp S, Chelune G, Ershler WB, Walston JD, Gordeuk VR, Berger NA, Reuben D, Prchal J, Rao SV, Roy CN, Supiano MA, Schrier SL, Cohen HJ (2014). A prospective randomized wait list control trial of intravenous iron sucrose in older adults with unexplained anemia and serum ferritin 20-200 ng/mL. Blood Cells Mol Dis, 53(4), 221-30. ()
    43. Sarangi S, Lanikova L, Kapralova K, Acharya S, Swierczek S, Lipton JM, Wolfe L, Prchal JT (2014). The homozygous VHL(D126N) missense mutation is associated with dramatically elevated erythropoietin levels, consequent polycythemia, and early onset severe pulmonary hypertension. Pediatr Blood Cancer, 61(11), 2104-6. ()
    44. Sangle N, Cook J, Perkins S, Teman CJ, Bahler D, Hickman K, Wilson A, Prchal J, Salama ME (2014). Myelofibrotic transformations of polycythemia vera and essential thrombocythemia are morphologically, biologically, and prognostically indistinguishable from primary myelofibrosis. Appl Immunohistochem Mol Morphol, 22(9), 663-8. ()
    45. Lorenzo FR, Huff C, Myllymki M, Olenchock B, Swierczek S, Tashi T, Gordeuk V, Wuren T, Ri-Li G, McClain DA, Khan TM, Koul PA, Guchhait P, Salama ME, Xing J, Semenza GL, Liberzon E, Wilson A, Simonson TS, Jorde LB, Kaelin WG Jr, Koivunen P, Prchal JT (2014). A genetic mechanism for Tibetan high-altitude adaptation. Nat Genet, 46(9), 951-6. ()
    46. Rondelli D, Goldberg JD, Isola L, Price LS, Shore TB, Boyer M, Bacigalupo A, Rambaldi A, Scarano M, Klisovic RB, Gupta V, Andreasson B, Mascarenhas J, Wetzler M, Vannucchi AM, Prchal JT, Najfeld V, Orazi A, Weinberg RS, Miller C, Barosi G, Silverman LR, Prosperini G, Marchioli R, Hoffman R (2014). MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood, 124(7), 1183-91. ()
    47. Tashi T, Feng T, Koul P, Amaru R, Hussey D, Lorenzo FR, RiLi G, Prchal JT (2014). High altitude genetic adaptation in Tibetans: no role of increased hemoglobin-oxygen affinity. Blood Cells Mol Dis, 53(1-2), 27-9. ()
    48. Zhang X, Zhang W, Ma SF, Desai AA, Saraf S, Miasniakova G, Sergueeva A, Ammosova T, Xu M, Nekhai S, Abbasi T, Casanova NG, Steinberg MH, Baldwin CT, Sebastiani P, Prchal JT, Kittles R, Garcia JG, Machado RF, Gordeuk VR (2014). Hypoxic response contributes to altered gene expression and precapillary pulmonary hypertension in patients with sickle cell disease. Circulation, 129(16), 1650-8. ()
    49. Dickinson RE, Milne P, Jardine L, Zandi S, Swierczek SI, McGovern N, Cookson S, Ferozepurwalla Z, Langridge A, Pagan S, Gennery A, Heiskanen-Kosma T, Hamalainen S, Seppanen M, Helbert M, Tholouli E, Gambineri E, Reykdal S, Gottfreethsson M, Thaventhiran JE, Morris E, Hirschfield G, Richter AG, Jolles S, Bacon CM, Hambleton S, Haniffa M, Bryceson Y, Allen C, Prchal JT, Dick JE, Bigley V, Collin M (2014). The evolution of cellular deficiency in GATA2 mutation. Blood, 123(6), 863-74. ()
    50. Kapralova K, Lanikova L, Lorenzo F, Song J, Horvathova M, Divoky V, Prchal JT (2014). RUNX1 and NF-E2 upregulation is not specific for MPNs, but is seen in polycythemic disorders with augmented HIF signaling. Blood, 123(3), 391-4. ()
    51. Christensen RD, Nussenzveig RH, Reading NS, Agarwal AM, Prchal JT, Yaish HM (2014). Variations in both alpha-spectrin (SPTA1) and beta-spectrin ( SPTB ) in a neonate with prolonged jaundice in a family where nine individuals had hereditary elliptocytosis. Neonatology, 105(1), 1-4. ()
    52. Reading NS, Sirdah MM, Tarazi IS, Prchal JT (2014). Detection of nine Mediterranean beta-thalassemia mutations in Palestinians using three restriction enzyme digest panels: a reliable method for developing countries. Hemoglobin, 38(1), 39-43. ()
    53. Ye Z, Liu CF, Lanikova L, Dowey SN, He C, Huang X, Brodsky RA, Spivak JL, Prchal JT, Cheng L (2014). Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cells. Stem Cells, 32(1), 269-78. ()
    54. Zhang X, Zhang W, Ma SF, Miasniakova G, Sergueeva A, Ammosova T, Xu M, Nekhai S, Nourai M, Wade MS, Prchal JT, Garcia JGN, Machado RF, Gordeuk VR (2014). Iron deficiency modifies gene expression variation induced by augmented hypoxia sensing. Blood Cells Mol Dis, 52(1), 35-45. ()
    55. Nussenzveig RH, Christensen RD, Prchal JT, Yaish HM, Agarwal AM (2014). Novel alpha-spectrin mutation in trans with alpha-spectrin causing severe neonatal jaundice from hereditary spherocytosis. Neonatology, 106(4), 355-7. ()

    Review

    1. Iolascon A, Bianchi P, Andolfo I, Russo R, Barcellini W, Fermo E, Toldi G, Ghirardello S, Rees D, Van Wijk R, Kattamis A, Gallagher PG, Roy N, Taher A, Mohty R, Kulozik A, De Franceschi L, Gambale A, De Montalembert M, Forni GL, Harteveld CL, Prchal J, SWG of red cell and iron of EHA and EuroBloodNet (2021). Recommendations for diagnosis and treatment of methemoglobinemia. [Review]. Am J Hematol, 96(12), 1666-1678. ()
    2. Stein BL, Gotlib J, Arcasoy M, Nguyen MH, Shah N, Moliterno A, Jamieson C, Pollyea DA, Scott B, Wadleigh M, Levine R, Komrokji R, Klisovic R, Gundabolu K, Kropf P, Wetzler M, Oh ST, Ribeiro R, Paschal R, Mohan S, Podoltsev N, Prchal J, Talpaz M, Snyder D, Verstovsek S, Mesa RA (2015). Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. [Review]. J Natl Compr Canc Netw, 13(4), 424-34. ()

    Case Report

    1. Bahr TM, Lozano-Chinga M, Agarwal AM, Meznarich JA, Yost CC, Li P, Reading NS, Prchal JT, Christensen RD (2020). A Novel Variant in G6PD (c.1375C>G) Identified from a Hispanic Neonate with Extreme Hyperbilirubinemia and Low G6PD Enzymatic Activity. Neonatology, 117(4), 532-535. ()
    2. Christensen RD, Yaish HM, Wiedmeier SE, Reading NS, Pysher TJ, Palmer CA, Prchal JT (2013). Neonatal death suspected to be from sepsis was found to be kernicterus with G6PD deficiency. Pediatrics, 132(6), e1694-8. ()
    3. Boonyawat B, Dhanraj S, Al Abbas F, Zlateska B, Grunenbaum E, Roifman CM, Steele L, Meyn S, Blanchette V, Scherer SW, Swierczek S, Prchal J, Zhu Q, Torgerson TR, Ochs HD, Dror Y (2013). Combined de-novo mutation and non-random X-chromosome inactivation causing Wiskott-Aldrich syndrome in a female with thrombocytopenia. J Clin Immunol, 33(7), 1150-5. ()

    Editorial

    1. Prchal JT, Reeves BN (2023). EnvIRONment modifies polycythemia vera. Blood, 141(17), 2042-2044. ()
    2. Iolascon A, Andolfo I, Russo R, Barcellini W, Fermo E, Toldi G, Ghirardello S, Rees D, Van Wijk R, Kattamis A, Gallagher PG, Roy N, Taher A, Mohty R, Kulozik A, De Franceschi L, Gambale A, De Montalembert M, Forni GL, Harteveld CL, Prchal J, Bianchi P (2021). Summary of Joint European Hematology Association (EHA) and EuroBloodNet Recommendations on Diagnosis and Treatment of Methemoglobinemia. Hemasphere, 5(12), e660. ()
    3. Song J, Christensen RD, Thiagarajan P, Prchal JT (2021). Does neocytolysis exist after descent from high altitude? Acta Physiol (Oxf), 233(3), e13713. ()
    4. Prchal JT, Gordeuk VR (2021). HIF-2 inhibitor, erythrocytosis, and pulmonary hypertension. Blood, 137(18), 2424-2425. ()
    5. Song J, Tashi T, Prchal JT (2019). Editorial Comment on: Inhibition of Suicidal Erythrocyte Death by Chronic Hypoxia by Tang et al. (From: Tang F, Feng L, Li R, Wang W, Liu H, Yang Q, Ge R-L. High Alt Med Biol 2019;20:112-119; DOI: 10.1089/ham.2017.0159). High Alt Med Biol, 20(2), 120-121. ()
    6. Mascarenhas J, Mesa R, Prchal J, Hoffman R (2014). Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials. Haematologica, 99(6), 945-9. ()

    Letter

    1. Lichtman MA, Prchal JT (2023). Measurement of red cell, plasma and blood volume: Essential components of diagnostic and research studies of oxygen transport. [Letter to the editor]. Blood Cells Mol Dis, 105, 102819. ()
    2. Reeves BN, Kim SJ, Song J, Wilson KJ, Henderson MW, Key NS, Pawlinski R, Prchal JT (2021). Tissue Factor Activity Is Increased in Neutrophils from JAK2 V617F-mutated Essential Thrombocythemia and Polycythemia Vera Patients. [Letter to the editor]. Am J Hematol, 97(2), E37-E40. ()
    3. Meznarich JA, Rets A, Agarwal AM, Christensen RD, Reading NS, Kuypers FA, Prchal JT (2021). Novel, de novo, beta-globin variant with decreased oxygen affinity (HBB:c.317T>A, "Hemoglobin St. George") in a healthy child with low oxygen saturations and anemia. [Letter to the editor]. Am J Hematol, 96(12), E448-E450. ()
    4. Kim SJ, Song J, Reading NS, Lautersztain J, Kutlar A, Agarwal AM, Coetzer TL, Prchal JT (2021). Novel mechanism of hereditary pyropoikilocytosis phenotype due to co-inheritance of Ξ² globin and Ξ± spectrin mutations. [Letter to the editor]. Am J Hematol, 96(5), E150-E154. ()
    5. Zhang X, Song J, Shah BN, Nekhai S, Miasnikova G, Sergueeva A, Prchal JT, Gordeuk VR (2020). Peripheral blood mononuclear cells show prominent gene expression by erythroid progenitors in diseases characterized by heightened erythropoiesis. [Letter to the editor]. Br J Haematol, 190(1), e42-e45. ()
    6. Gordeuk VR, Miasnikova GY, Sergueeva AI, Lorenzo FR, Zhang X, Song J, Stockton DW, Prchal JT (2019). Thrombotic risk in congenital erythrocytosis due to up-regulated hypoxia sensing is not associated with elevated hematocrit. [Letter to the editor]. Haematologica, 105(3), e87-e90. ()
    7. Mascarenhas J, Kosiorek H, Prchal J, Yacoub A, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Salama ME, Weinberg RS, Rampal R, Goldberg JD, Mesa R, Dueck AC, Hoffman R (2019). A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. [Letter to the editor]. Leukemia, 33(12), 2974-2978. ()
    8. Gangaraju R, Carroll AJ, Prchal JT (2019). Response to interferon treatment in essential thrombocythemia with inv(3)(q21q26). [Letter to the editor]. Ann Hematol. ()
    9. Swierczek S, Lima LT, Tashi T, Kim SJ, Gregg XT, Prchal JT (2015). Presence of polyclonal hematopoiesis in females with Ph-negative myeloproliferative neoplasms. [Letter to the editor]. Leukemia, 29(12), 2432-4. ()
    10. Sergueeva AI, Miasnikova GY, Polyakova LA, Nouraie M, Prchal JT, Gordeuk VR (2015). Complications in children and adolescents with Chuvash polycythemia. [Letter to the editor]. Blood, 125(2), 414-5. ()
    11. Salama ME, Swierczek SI, Tashi T, Warby CA, Reading NS, Prchal JT (2014). Calreticulin mutated prefibrotic-stage myelofibrosis and PMF represent an independent clone from coexisting CLL. [Letter to the editor]. Blood, 124(10), 1691-2. ()
    12. Wang L, Swierczek SI, Lanikova L, Kim SJ, Hickman K, Walker K, Wang K, Drummond J, Doddapaneni H, Reid JG, Muzny DM, Gibbs RA, Wheeler DA, Prchal JT (2014). The relationship of JAK2(V617F) and acquired UPD at chromosome 9p in polycythemia vera. [Letter to the editor]. Leukemia, 28(4), 938-41. ()
    13. Wang L, Swierczek SI, Drummond J, Hickman K, Kim SJ, Walker K, Doddapaneni H, Muzny DM, Gibbs RA, Wheeler DA, Prchal JT (2014). Whole-exome sequencing of polycythemia vera revealed novel driver genes and somatic mutation shared by T cells and granulocytes. [Letter to the editor]. Leukemia, 28(4), 935-8. ()

    Other

    1. Zhang X, Song J, Shah BN, Han J, Hassan T, Miasniakova G, Sergueeva A, Nekhai S, Machado RF, Gladwin MT, Saraf SL, Prchal JT, Gordeuk VR (2023). Publisher Correction: Gene expression changes in sickle cell reticulocytes and their clinical associations. Sci Rep (13(1), p. 15225). England. ()